Godelieve de Bree
Overview
Explore the profile of Godelieve de Bree including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
158
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Blenkinsop A, Sofocleous L, Di Lauro F, Kostaki E, van Sighem A, Bezemer D, et al.
Stat Methods Med Res
. 2025 Feb;
:9622802241309750.
PMID: 39936344
In stopping the spread of infectious diseases, pathogen genomic data can be used to reconstruct transmission events and characterize population-level sources of infection. Most approaches for identifying transmission pairs do...
2.
de Taeye S, Faye L, Morel B, Schriek A, Umotoy J, Yuan M, et al.
Plant Biotechnol J
. 2024 Nov;
23(1):4-16.
PMID: 39563066
Prevention of severe COVID-19 disease by SARS-CoV-2 in high-risk patients, such as immuno-compromised individuals, can be achieved by administration of antibody prophylaxis, but producing antibodies can be costly. Plant expression...
3.
Blenkinsop A, Pantazis N, Kostaki E, Sofocleous L, van Sighem A, Bezemer D, et al.
J Infect Dis
. 2024 Jul;
230(4):e881-e894.
PMID: 38976562
Background: Men and women with a migration background comprise an increasing proportion of incident human immunodeficiency virus (HIV) cases across Western Europe. Methods: To characterize sources of transmission in local...
4.
Bermejo-Jambrina M, van der Donk L, van Hamme J, Wilflingseder D, de Bree G, Prins M, et al.
EMBO J
. 2024 Feb;
43(7):1135-1163.
PMID: 38418557
Dysregulated immune responses contribute to the excessive and uncontrolled inflammation observed in severe COVID-19. However, how immunity to SARS-CoV-2 is induced and regulated remains unclear. Here, we uncover the role...
5.
Verveen A, Wynberg E, van Willigen H, Davidovich U, Lok A, Moll van Charante E, et al.
J Psychosom Res
. 2023 Oct;
175:111520.
PMID: 37852167
Objective: To investigate to what extent individuals report clinically relevant levels of depression, anxiety, post-traumatic stress disorder (PTSD) symptoms and concentration problems up to 12 months following COVID-19 symptom onset,...
6.
Verveen A, Verfaillie S, Visser D, Csorba I, Coomans E, Koch D, et al.
BMJ Open
. 2023 Jul;
13(6):e072611.
PMID: 37399444
Introduction: The risk factors for persistent fatigue and cognitive complaints after infection with SARS-CoV-2 and the underlying pathophysiology are largely unknown. Both clinical factors and cognitive-behavioural factors have been suggested...
7.
Michels E, van Amstel R, van Linge C, Schuurman A, Reijnders T, Sulzer T, et al.
Eur Respir J
. 2023 Apr;
62(1).
PMID: 37080568
Background: Coronavirus disease 2019 (COVID-19)-induced mortality occurs predominantly in older patients. Several immunomodulating therapies seem less beneficial in these patients. The biological substrate behind these observations is unknown. The aim...
8.
Verveen A, Wynberg E, van Willigen H, Davidovich U, Lok A, Moll van Charante E, et al.
BMC Med
. 2022 Nov;
20(1):422.
PMID: 36324167
Background: Currently, there is limited evidence about the long-term impact on physical, social and emotional functioning, i.e. health-related quality of life (HRQL) after mild or moderate COVID-19 not requiring hospitalization....
9.
Verveen A, Wynberg E, van Willigen H, Boyd A, de Jong M, de Bree G, et al.
Open Forum Infect Dis
. 2022 Apr;
9(5):ofac127.
PMID: 35415196
Background: Severe fatigue can persist for months after coronavirus disease 2019 (COVID-19) onset. This longitudinal study describes fatigue severity and its determinants up to 12 months after illness onset across...
10.
Dijkstra M, Prins H, Prins J, Reiss P, Boucher C, Verbon A, et al.
BMJ Open
. 2021 Nov;
11(11):e048582.
PMID: 34845066
Purpose: Initiation of combination antiretroviral therapy (cART) during acute or early HIV-infection (AEHI) limits the size of the viral reservoir and preserves immune function. This renders individuals who started cART...